Skip to main content
Erschienen in:

28.09.2020 | COVID-19 | IM - REVIEW Zur Zeit gratis

Current treatment of COVID-19 in renal patients: hope or hype?

verfasst von: Palumbo Roberto, Londrino Francesco, Cordova Emanuela, Gambardella Giorgia, Niscola Pasquale, Dominijanni Sara

Erschienen in: Internal and Emergency Medicine | Ausgabe 8/2020

Einloggen, um Zugang zu erhalten

Abstract

To date the severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2), known as COVID-19, is for clinicians the most difficult global therapeutic problem. In this landscape, the management of patients with chronic kidney disease, acute kidney injury or patients undergoing immunosuppressant therapies for kidney transplant or glomerular diseases, represent a clinical challenge for nephrologists, especially in patients with severe acute lung involvement. Therefore in this setting, due to the lack of anti-COVID treatment schedules, tailored management is mandatory to reduce the side effects, as consequence of impaired renal function and drugs interactions. We report the main treatment actually used against SARS-CoV-2, underlining its possible use in the nephropatic patients and the central role of nephrologists to improve the clinical outcome.
Literatur
4.
Zurück zum Zitat Alberici F, Del Barba E, Manenti C et al (2020) Gestione del paziente in dialisi e con trapianto di rene in corso di infezione da coronavirus Covid 19. Giornale Italiano di nefrologia Anno 37:2 Alberici F, Del Barba E, Manenti C et al (2020) Gestione del paziente in dialisi e con trapianto di rene in corso di infezione da coronavirus Covid 19. Giornale Italiano di nefrologia Anno 37:2 
5.
Zurück zum Zitat Ying-Hui J, Lin C, Zhen-Shun C et al (2020) A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res 7:4 Ying-Hui J, Lin C, Zhen-Shun C et al (2020) A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res 7:4
6.
Zurück zum Zitat Pan Z, Yanbing D, Xia W et al (2020) The epidemiology, diagnosis and treatment of COVID-19. Antimicrob Agents 55(5):105955CrossRef Pan Z, Yanbing D, Xia W et al (2020) The epidemiology, diagnosis and treatment of COVID-19. Antimicrob Agents 55(5):105955CrossRef
9.
Zurück zum Zitat Zhonghua Jie He He Hu Xi Za Zhi, (2020) Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia, Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. 43(3):185–188. https://doi.org/10.3760/cma.j.issn.1001-0939.2020.03.009. Chinese Zhonghua Jie He He Hu Xi Za Zhi, (2020) Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia, Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. 43(3):185–188. https://​doi.​org/​10.​3760/​cma.​j.​issn.​1001-0939.​2020.​03.​009. Chinese
19.
Zurück zum Zitat Borba MGS , Almeida Val FF, Sampio VS (2020) Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open 2020 3(4):e208857 Borba MGS , Almeida Val FF, Sampio VS (2020) Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial.  JAMA Netw Open 2020 3(4):e208857
20.
Zurück zum Zitat Retallack H, Di Lullo E, Arias C et al (2016) Zika virus cell tropism in the developing human brain and inhibition by azithromycin. Proc Natl Acad Sci U S A 113(50):14408–14413 (Epub 2016 Nov 29)CrossRefPubMedPubMedCentral Retallack H, Di Lullo E, Arias C et al (2016) Zika virus cell tropism in the developing human brain and inhibition by azithromycin. Proc Natl Acad Sci U S A 113(50):14408–14413 (Epub 2016 Nov 29)CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Hydroxychloroquine vs. Azithromycin for hospitalized patients with suspected or confirmed COVID-19, HAHPS (NCT04329832) Latest version (submitted April 7, 2020) on ClinicalTrials.gov, Accessed May 02, 2020 Hydroxychloroquine vs. Azithromycin for hospitalized patients with suspected or confirmed COVID-19, HAHPS (NCT04329832) Latest version (submitted April 7, 2020) on ClinicalTrials.gov, Accessed May 02, 2020
24.
Zurück zum Zitat Azithromycin for COVID-19 Treatment in Outpatients Nationwide, ACTION (NCT04332107) Latest version (submitted April 24, 2020) on ClinicalTrials.gov, Accessed May 02, 2020 Azithromycin for COVID-19 Treatment in Outpatients Nationwide, ACTION (NCT04332107) Latest version (submitted April 24, 2020) on ClinicalTrials.gov, Accessed May 02, 2020
26.
Zurück zum Zitat Katzung BG, Masters SB, Trevor AJ (2011) Farmacologia generale e clinica. X Edizione Italiana a cura del Prof P. Preziosi. pag 931–961 Katzung BG, Masters SB, Trevor AJ (2011) Farmacologia generale e clinica. X Edizione Italiana a cura del Prof P. Preziosi. pag 931–961
27.
Zurück zum Zitat Chu CM, Cheng VCC, Hung IFN (2004) Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 59:252–256CrossRefPubMedPubMedCentral Chu CM, Cheng VCC, Hung IFN (2004) Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 59:252–256CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Chan JF, Yao Y, Yeung ML, Deng W, Bao L, Jia L, Li F, Xiao C, Gao H, Yu P, Cai JP, Chu H, Zhou J, Chen H, Qin C, Yuen KY (2015) Treatment with lopinavir/ritonavir or interferon-ß1b Improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis 212(12):1904–1913. https://doi.org/10.1093/infdis/jiv392(Epub 2015 Jul 21)CrossRefPubMed Chan JF, Yao Y, Yeung ML, Deng W, Bao L, Jia L, Li F, Xiao C, Gao H, Yu P, Cai JP, Chu H, Zhou J, Chen H, Qin C, Yuen KY (2015) Treatment with lopinavir/ritonavir or interferon-ß1b Improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis 212(12):1904–1913. https://​doi.​org/​10.​1093/​infdis/​jiv392(Epub 2015 Jul 21)CrossRefPubMed
32.
Zurück zum Zitat Yao T-T, Qian J-D, ZhuW Y, Wang-Y, Wang GQ (2020) A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—a possible reference for coronavirus disease‐19 treatment option. J Med Virol 92(6):556–563. https://doi.org/10.1002/jmv.25729 Yao T-T, Qian J-D, ZhuW Y, Wang-Y, Wang GQ (2020) A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—a possible reference for coronavirus disease‐19 treatment option. J Med Virol 92(6):556–563.  https://​doi.​org/​10.​1002/​jmv.​25729
33.
Zurück zum Zitat Lim J, Jeon S, Shin H-Y et al (2020) Case of the index patient who caused tertriary transmission of coronovirus disease 2019 in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative RT-PCR. J Korean Med Sci 35(6):e79CrossRefPubMedPubMedCentral Lim J, Jeon S, Shin H-Y et al (2020) Case of the index patient who caused tertriary transmission of coronovirus disease 2019 in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative RT-PCR. J Korean Med Sci 35(6):e79CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Benn P, Ascar MR (2009) Role of darunavir in the management of HIV infection. HIV/AID (Auckl) 1:31–39 Benn P, Ascar MR (2009) Role of darunavir in the management of HIV infection. HIV/AID (Auckl) 1:31–39
36.
Zurück zum Zitat Santos JR, Curran A, Navarro-Mercade J et al (2019) Simplification of antiretroviral treatment from darunavir/ritonavir monotherapy to darunavir/cobicistat monotherapy: effectiveness and safety in routine clinical practice. AIDS Res Hum Retroviruses 35(6):513–518CrossRefPubMed Santos JR, Curran A, Navarro-Mercade J et al (2019) Simplification of antiretroviral treatment from darunavir/ritonavir monotherapy to darunavir/cobicistat monotherapy: effectiveness and safety in routine clinical practice. AIDS Res Hum Retroviruses 35(6):513–518CrossRefPubMed
37.
Zurück zum Zitat Efficacy and safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCov (NCT04252274). Latest version (submitted January 29, 2020) on ClinicalTrials.gov. Accessed May 02, 2020 Efficacy and safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCov (NCT04252274). Latest version (submitted January 29, 2020) on ClinicalTrials.gov. Accessed May 02, 2020
38.
Zurück zum Zitat A randomised, open, controlled trial for darunavir/cobicistat or Lopinavir/ritonavir combined with thymosin a1 in the treatment of 2019-nCoV pneumonia. (ChiCTR2000029541) Latest version submitted Febrary 12, 2020 on https://www.chictr.org.cn(Chinese Clinical Trial Registry) Accessed May 02, 2020 A randomised, open, controlled trial for darunavir/cobicistat or Lopinavir/ritonavir combined with thymosin a1 in the treatment of 2019-nCoV pneumonia. (ChiCTR2000029541) Latest version submitted Febrary 12, 2020 on https://​www.​chictr.​org.​cn(Chinese Clinical Trial Registry) Accessed May 02, 2020
39.
Zurück zum Zitat Società Italiana di Malattie Infettive e Tropicali (SIMIT) (2020) Vademecum per la cura delle persone con malattia da COVID-19. Edizione 2.0. Gruppo collaborativo – Terapia COVID-19 Lombardia Società Italiana di Malattie Infettive e Tropicali (SIMIT) (2020) Vademecum per la cura delle persone con malattia da COVID-19. Edizione 2.0. Gruppo collaborativo – Terapia COVID-19 Lombardia
50.
Zurück zum Zitat Jordan PC, Stevens SK (2018) Nucleosides for the treatment of respiratory RNA virus infections. Antiviral Chem Chemother 26:1–19CrossRef Jordan PC, Stevens SK (2018) Nucleosides for the treatment of respiratory RNA virus infections. Antiviral Chem Chemother 26:1–19CrossRef
56.
Zurück zum Zitat Liu C, Qiongqiong Z, Li Y et al (2020) Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent Sci 6(3):315–331CrossRefPubMed Liu C, Qiongqiong Z, Li Y et al (2020) Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent Sci 6(3):315–331CrossRefPubMed
58.
Zurück zum Zitat Morra ME, Van Thanh L, Kamel MG et al (2018) Clinical outcomes of current medical approaches for Middle East respiratory syndrome: a systematic review and meta-analysis. Rev Med Virol 28(3):e1977. https://doi.org/10.1002/rmv.1977 Morra ME, Van Thanh L, Kamel MG et al (2018)  Clinical outcomes of current medical approaches for Middle East respiratory syndrome: a systematic review and meta-analysis. Rev Med Virol  28(3):e1977. https://​doi.​org/​10.​1002/​rmv.​1977
64.
Zurück zum Zitat Xu X, Han M, Li T et al (2020) Effective treatment of severe COVID-19 patients with Tocilizumab. Accessed 19 Mar 2020 Xu X, Han M, Li T et al (2020) Effective treatment of severe COVID-19 patients with Tocilizumab. Accessed 19 Mar 2020
67.
Zurück zum Zitat A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia (COVACTA) (NCT04320615). Latest version (submitted March 23, 2020) on ClinicalTrials.gov, Accessed May 02, 2020 A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia (COVACTA) (NCT04320615). Latest version (submitted March 23, 2020) on ClinicalTrials.gov, Accessed May 02, 2020
68.
Zurück zum Zitat Genentech, Inc, South San Francisco, CA. Actemra use in Coronavirus Disease 2019 (COVID-19) standard reply letter. (2020) Genentech, Inc, South San Francisco, CA. Actemra use in Coronavirus Disease 2019 (COVID-19) standard reply letter. (2020)
71.
Zurück zum Zitat Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients (NCT04264858) Latest version (submitted February 8, 2020) on ClinicalTrials.gov, Accessed May 02, 2020 Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients (NCT04264858) Latest version (submitted February 8, 2020) on ClinicalTrials.gov, Accessed May 02, 2020
72.
Zurück zum Zitat Convalescent plasma for the treatment of severe and critical novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial (ChiCTR2000029757) Latest Version (submitted March 9, 2020). https://www.chictr.org.cn Convalescent plasma for the treatment of severe and critical novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial (ChiCTR2000029757) Latest Version (submitted March 9, 2020). https://​www.​chictr.​org.​cn
77.
Zurück zum Zitat Chu KH, Tsang WK, Tang CS et al (2005) Acute renal impairment in coronavirus-associated severe acute respiratory syndrome. Kidney Int 67:698–705CrossRefPubMedPubMedCentral Chu KH, Tsang WK, Tang CS et al (2005) Acute renal impairment in coronavirus-associated severe acute respiratory syndrome. Kidney Int 67:698–705CrossRefPubMedPubMedCentral
78.
Zurück zum Zitat Jung JY, Park BH, Hong SB et al (2011) Acute kidney injury in critically ill patients with pandemic influenza A pneumonia 2009 in Korea: a multicenter study. J Crit Care 26:577–585CrossRefPubMed Jung JY, Park BH, Hong SB et al (2011) Acute kidney injury in critically ill patients with pandemic influenza A pneumonia 2009 in Korea: a multicenter study. J Crit Care 26:577–585CrossRefPubMed
79.
Metadaten
Titel
Current treatment of COVID-19 in renal patients: hope or hype?
verfasst von
Palumbo Roberto
Londrino Francesco
Cordova Emanuela
Gambardella Giorgia
Niscola Pasquale
Dominijanni Sara
Publikationsdatum
28.09.2020
Verlag
Springer International Publishing
Schlagwort
COVID-19
Erschienen in
Internal and Emergency Medicine / Ausgabe 8/2020
Print ISSN: 1828-0447
Elektronische ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-020-02510-0

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Innere Medizin

Vorhofflimmern: Antikoagulation vor Schlaganfall von Vorteil

Erleiden Menschen mit Vorhofflimmern einen ischämischen Schlaganfall, ist dieser weniger schwer, auch sind Infarktgröße und Blutungsrisiko geringer, wenn sie zuvor orale Antikoagulanzien erhalten haben. Die Art der Antikoagulation spielt dabei keine Rolle.

Frühe CLL-Therapie: BTK-Hemmer verlängert EFS und PFS, aber nicht OS

Auch nach sechs Jahren ergibt sich kein Überlebensvorteil einer Therapie mit dem BTK-Hemmer Ibrutinib für Menschen mit frühem CLL-Stadium und erhöhtem Progressionsrisiko. Die Progressionsrate wird mit der Behandlung jedoch um über 80% gesenkt.

Mehr Cholesterin im Essen = höheres Herzinfarktrisiko

Je mehr Cholesterin man täglich über die Nahrung zu sich nimmt, desto höher ist offenbar das Herzinfarktrisiko – das legt eine Studie mit US-Veteranen zumindest für Männer nahe.

Antikoagulation bei Vorhofflimmern: Sind DOAK noch zu toppen?

Gegen Thromboembolien so wirksam wie ein DOAK, bei zugleich geringerem Blutungsrisiko – werden Faktor-XI-Hemmer als neue Antikoagulanzien dieser Erwartung gerecht? Eine aktuell publizierte Vergleichsstudie gibt darüber Aufschluss.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.